Evidence map›Paper›PMID 40616664›Full record

ArticleAnalytical and bioanalytical chemistry2025

A pseudotargeted metabolomics method for phosphatidyl amino acid analysis in chemotherapy-resistant cells and exosomes.

Meiyu Gao, Yu Wu, Huihui Yin, Qiang Wang, Yuan Tian, Zunjian Zhang, Fengguo Xu, Pei Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Meiyu GaoDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China.
Yu WuDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China.
Huihui YinDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China.
Qiang WangDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China.
Yuan TianKey Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), Nanjing, 210009, P. R. China.
Zunjian ZhangKey Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), Nanjing, 210009, P. R. China.
Fengguo XuDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China. fengguoxu@cpu.edu.cn.
Pei ZhangDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China. peizhang@cpu.edu.cn.

Funding

National Natural Science Foundation of China 82104117National Natural Science Foundation of China 82273896National Natural Science Foundation of China 82473883National Natural Science Foundation of China U24A20788
6 · The paper itself

Abstract

Phosphatidyl amino acids (p-AAs) are metabolites characterized by the phosphorylation of the hydroxyl, amino, carboxyl, and thiol groups of amino acids. Previous research has primarily focused on the phosphorylation sites within macromolecular proteins, with a particular emphasis on typical O-p-AAs. In this study, we established a prediction library of p-AAs based on existing knowledge. To improve detection rates of p-AAs in biological samples, we employed a chemical labeling-based LC-MS/MS method, utilizing p-[3,5-(dimethylamino)-2,4,6-triazine] benzene-1-sulfonyl piperazine (Tmt-PP) and its deuterated form (d12-Tmt-PP) as paired labeling reagents. A preliminary identification was performed by matching characteristic MS fragments with available standards. Additionally, strategies such as in vitro methods were implemented for further identification. The phosphatase treatment aids in identifying phosphate-modified metabolites by dephosphorylating them, while cell extract incubation helps determine if novel phosphorylated amino acids are generated in vivo. Ultimately, we identified 11 p-AAs, 6 of which are novel metabolites reported for the first time. A pseudotargeted metabolomics method covering 11 identified p-AAs was established and applied to investigate the differences between cisplatin-resistant non-small cell lung cancer (NSCLC) cells and their parental cells, as well as their derived exosomes. This approach enhances our understanding of the role of p-AAs in various health and disease conditions and contributes to the discovery of additional novel phosphatidyl metabolites.

Indexed as

Amino AcidsDrug Resistance, NeoplasmExosomesLung NeoplasmsMetabolomicsAntineoplastic AgentsCell Line, TumorChromatography, LiquidCisplatinHumansTandem Mass SpectrometryAmino AcidsAntineoplastic AgentsCisplatinChemical labelingChemotherapy resistanceExosomeLC–MS/MSPhosphatidyl amino acids

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.